| Literature DB >> 30287417 |
Maryam Zolnoori1,2,3, Kin Wah Fung1, Paul Fontelo1, Hadi Kharrazi4, Anthony Faiola5, Yi Shuan Shirley Wu6, Virginia Stoffel7, Timothy Patrick8.
Abstract
BACKGROUND: Nonadherence to antidepressants is a major obstacle to deriving antidepressants' therapeutic benefits, resulting in significant burdens on the individuals and the health care system. Several studies have shown that nonadherence is weakly associated with personal and clinical variables but strongly associated with patients' beliefs and attitudes toward medications. Patients' drug review posts in online health care communities might provide a significant insight into patients' attitude toward antidepressants and could be used to address the challenges of self-report methods such as patients' recruitment.Entities:
Keywords: antidepressive agents; attitude; chronic disease; community networks; data mining; depression; framework method; internet; medication adherence; patient-centered care; perception; social media
Year: 2018 PMID: 30287417 PMCID: PMC6876546 DOI: 10.2196/10726
Source DB: PubMed Journal: JMIR Ment Health ISSN: 2368-7959
Figure 1A summary of the research methodology of the study. IAA: interannotator agreement; ANOVA: analysis of variance; API: application programming interface; IRB: institutional review board.
Factors affecting patients’ attitudes toward antidepressants (identified by a comprehensive review of the literature).
| Category | Factors in each category |
| Pharmacological treatment factors | Perceived effectiveness Perceived necessity Perceived concern Adverse drug reaction Perceived distress from the adverse effect |
| Health care system factors | Patient-provider relationship Health care setting Affordability of the treatment |
| Social-cognitive and psychological factors | Stigma and cultural related factors Partners’ support |
| Patient-related factors | General concern and necessity Knowledge about pharmacological aspects of medication Sociodemographic factors Educational level |
| Depression factors | Depression severity, type, and duration Patient insight about depression |
Themes and subthemes used in the final analytical framework with examples.
| Themes | Description | Example |
| Adverse drug reactions-presence or absence | If the patient explicitly reported experiencing ADRsa associated with the drug consumption. | “Effexor XR gave me horrible nightmares and I kept waking up.” |
| Perceived distress from ADRs-high | If the patient explicitly mentioned that they suffered from ADRs, used any qualifiers indicating severe ADRs, or indicated functional problems such as limitation in daily functioning because of ADRs. | “The side effects are intolerable.” |
| Perceived distress from ADRs-low | If the patient explicitly mentioned that the ADRs were tolerable and/or used qualifiers indicating mildness/transience persistency of ADRs. | “Any side effects were, for me, tolerable compared to the benefits.” |
| Perceived distress from ADRs-medium | If the perceived distress form ADR cannot be labeled as high or low, then it is medium. | “I suffered from headache.” |
| Withdrawal symptoms-presence or absence | If the patient explicitly reported experiencing any sign/symptoms associated with the process of dosage reduction or drug discontinuation. | “I weaned slowly and I feel nauseous a lot.” |
| WDb-perceived distress-high | If the patients explicitly mentioned they suffered from withdrawal symptoms, functional problems associated with the WDs, or they used qualifiers indicating the severity of a specific WD. | “The withdrawal symptoms are horrible |
| WD-perceived distress-low | If the patient explicitly mentioned that the WDs were tolerable or used qualifiers indicting mildness/transience of WDs. | “Withdrawal was fine; When I stopped the drug, I had mild dizziness.” |
| Perceived distress from WDs-medium | If the perceived distress form WD cannot be labeled as high or low, then it is medium. | “When I tried to stop the drug, I had some dizziness.” |
| Drug effectiveness-effectiveness | A drug is effective if the patient reported that depression symptoms improved or resolved after drug consumption. | “For the first few weeks it helped me feel better.” |
| Drug effectiveness-ineffectiveness | A drug is ineffective if the patient reported that depression symptoms became worse or stayed the same. | “It did not help me at all.” |
| Patient-physician interaction-positive | A patient-physician interaction is positive, if the patient expressed their satisfaction from communications with clinicians. | “Success with these meds truly depends on staying in touch with your physician.” |
| Patient-physician interaction-negative | A patient-physician interaction is negative, if the patient expressed their dissatisfaction from communications with clinicians. | “Doctors do not understand the crazy side effects of starting this class of drugs.” |
| Lack of knowledge | If the patient complained that they did not receive sufficient information about ADRs or WDs of the drugs and the mechanism of its management. | “No one informed me of the withdrawal nightmare.” |
| Experience of WD-unintentional | If the patient explicitly mentioned that they forgot to take medication (missing dosages) or ran out of medication, the discontinuation is unintentional. | “When I miss a day I feel very spaced out, thick, groggy, sad.” |
| Experience of WD-intentional | If the patient explicitly mentioned that they stopped (discontinue) the medication or they are in the process of discontinuation (weaning off or tapering off). | “I had to stop taking it.” |
aADRs: adverse drug reactions.
bWD: withdrawal symptoms.
Sample statistics for reviews posted between February 2001 and September 2016 (N=892).
| Sample statistics | Sample | |
| Number of reviews with text, n (%) | 887 (99.4) | |
| Number of reviews provided information for the variables of this study, n (%) | 879 (98.5) | |
| Rated as 1 | 195 (22.2) | |
| Rated as 2 | 104 (11.8) | |
| Rated as 3 | 152 (17.3) | |
| Rated as 4 | 209 (23.8) | |
| Rated as 5 | 219 (24.9) | |
| Female | 680 (76.2) | |
| Male | 212 (23.8) | |
| Mean (SD) | 37 (12.03) | |
| Median (range) | 35 (14-83) | |
| <20 | 49 (5.6) | |
| 20-29 | 242 (27.5) | |
| 30-39 | 249 (28.3) | |
| 40-49 | 200 (22.7) | |
| 50-59 | 106 (12.1) | |
| ≤60 | 33 (3.8) | |
| Mean (SD) | 18 (31.7) | |
| Median (range) | 5 (1 day-240 months [20 years]) | |
| <1 month | 215 (24.5) | |
| 1 to <3 months | 116 (13.2) | |
| 3 to <6 months | 120 (13.6) | |
| 6 months to <1 year | 125 (14.2) | |
| 1 to <2 years | 82 (9.3) | |
| 2 to <5 years | 128 (14.6) | |
| 5 to <10 years | 66 (7.5) | |
| ≥10 years | 27 (3.1) | |
aAverage of rating: 3.16.
Frequency of variables in the dataset.
| Variables | Frequency, n (%) | |
| Presence | 823 (93.6) | |
| Absence | 56 (6.4) | |
| High | 483(54.9) | |
| Medium | 230 (26.2) | |
| Low | 166(18.9) | |
| Effectiveness | 524 (59.6) | |
| Effectiveness-ineffectiveness | 120 (13.6) | |
| Ineffectiveness | 235 (26.8) | |
| Negative | 47 (5.3) | |
| Positive | 62 (7.1) | |
| Negative-positive | 4 (0.5) | |
| Missing value | 766 (87.1) | |
| Presence | 60 (6.8) | |
| Absence | 819 (93.2) | |
| No experience | 508 (57.8) | |
| Experience | 371 (42.2) | |
| No report | 831 (94.5) | |
| Reported | 48 (5.5) | |
| No report | 639 (72.7) | |
| Reported | 240 (27.3) | |
Coefficients of the variables in the predictive model.
| Variable | Coefficient | SE | ||
| Experience of ADRa | −0.51 | 1.17e-01 | <.001 | |
| ADR-PDb-low | 1.94 | 1.87e-01 | <.001 | |
| ADR-PD-medium | 0.81 | 1.58e-01 | <.001 | |
| Effectiveness-ineffectiveness | −0.87 | 1.94e-01 | <.001 | |
| Ineffectiveness | −3.98 | 2.12e-01 | <.001 | |
| Experience of withdrawal | −0.7 | 1.38e-01 | <.001 | |
| Complaint of the lack of knowledge | −0.43 | 3.22e-01 | .17 | |
| Duration | 0.00025 | 8.44e-05 | .002 | |
aADR: adverse drug reactions.
bADR-PD: perceived distress from ADRs.